Amgen discontinues Alzheimer’s prevention drug trials

You are here: Home > Biotech > Current Article

Amgen discontinues Alzheimer’s prevention drug trials

By Staff Report / Thursday, July 11th, 2019 / Comments Off on Amgen discontinues Alzheimer’s prevention drug trials

Thousand Oaks biotech giant Amgen, along with partners Novartis and Banner Alzheimer’s Institute, are discontinuing a clinical research program that was aimed at preventing or delaying the onset of Alzheimer’s disease in at-risk individuals. The company announced the news in a July 11 news release, which stated that “after a review of clinical data, sponsors…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.